Atosiban: The Oxytocin Antagonist in Clinical Practice

Atosiban (marketed as Tractocile) is a synthetic nonapeptide that acts as a competitive oxytocin receptor antagonist with additional affinity for the vasopressin V1a receptor. It is the only oxytocin receptor blocker approved for clinical use as a tocolytic drug – an agent that suppresses uterine contractions to delay preterm labour. Approved by the European Medicines Agency in 2000, atosiban has become a cornerstone of preterm labour management across Europe, Asia, and Latin America. This article provides a comprehensive review of atosiban’s pharmacology, clinical evidence, dosing, side-effect profile, and position within the broader landscape of tocolytic drugs.

The Clinical Problem: Preterm Labour

Preterm birth – delivery before 37 completed weeks of gestation – affects approximately 11% of pregnancies worldwide and is the leading cause of neonatal morbidity and mortality (Blencowe et al., 2012). Preterm labour is characterised by regular uterine contractions that produce cervical change before term, and its management centres on delaying delivery long enough to administer antenatal corticosteroids for foetal lung maturation and, where necessary, to facilitate maternal transfer to a tertiary care centre.

The rationale for tocolytic therapy is not to prevent preterm birth entirely – no tocolytic has been shown to improve long-term neonatal outcomes through prolongation of pregnancy alone – but to buy time. A delay of 48 hours is typically sufficient for corticosteroid benefit, and this is the benchmark against which tocolytic drugs including atosiban are evaluated.

Pharmacology of Atosiban

Mechanism of Action

Atosiban is a desamino analogue of oxytocin ([1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn]-oxytocin) that acts as a competitive antagonist at the oxytocin receptor (OXTR) on myometrial smooth muscle cells. By occupying the orthosteric binding site on OXTR, atosiban prevents endogenous oxytocin from activating the Gq/11-coupled signalling cascade that normally leads to phospholipase C activation, inositol trisphosphate (IP3) generation, intracellular calcium release, and myometrial contraction (Akerlund et al., 1999).

Atosiban also binds the vasopressin V1a receptor with lower affinity, acting as a mixed agonist-antagonist at this site. The V1a receptor contributes to uterine contractility, so this additional pharmacological action may enhance atosiban’s tocolytic efficacy. However, it also introduces theoretical concerns about vasopressin-related effects, though these have not proven clinically significant at therapeutic doses (Manning et al., 2008). For a broader overview of how oxytocin receptor antagonists work across research and clinical settings, see our companion article.

Pharmacokinetics

Atosiban is administered intravenously, following a three-step protocol:

1. Initial bolus: 6.75 mg administered over 1 minute
2. High-dose infusion: 300 µg/min (18 mg/h) for 3 hours
3. Maintenance infusion: 100 µg/min (6 mg/h) for up to 45 hours

The total maximum treatment duration is 48 hours, with a cumulative dose not exceeding 330 mg. Atosiban has a plasma half-life of approximately 18 minutes, reaching steady-state concentrations within 1 hour of initiating infusion. It is metabolised primarily by peptidases in the plasma and liver, and its metabolites are excreted renally (Goodwin et al., 1995).

The rapid onset and short half-life of atosiban offer a practical advantage: if an adverse effect occurs or tocolysis is no longer indicated, the drug’s effects dissipate quickly upon cessation of infusion.

Receptor Selectivity

Compared with newer oxytocin receptor antagonists such as barusiban (approximately 300-fold OXTR selectivity over V1a), atosiban has relatively modest selectivity. Its Ki values are approximately 7 nM for OXTR and 60 nM for V1a in human tissue (Pierzynski et al., 2004). While this selectivity profile is adequate for tocolytic use, it has motivated the development of more selective alternatives for potential research and clinical applications where vasopressin cross-reactivity could confound results or produce unwanted effects.

Clinical Evidence

Pivotal Trials: Atosiban vs. Placebo

The key efficacy data for atosiban come from two large randomised, double-blind, placebo-controlled trials. Romero et al. (2000) enrolled 531 women with threatened preterm labour between 20 and 33 weeks of gestation and compared intravenous atosiban with placebo. Atosiban significantly increased the proportion of women who remained undelivered at 48 hours (59.6% vs. 47.7%, p = 0.0003) and at 7 days (78.4% vs. 72.1%), confirming its efficacy as a short-term tocolytic.

However, the primary endpoint of delivery delayed to 28 days or to 37 weeks was not met in the intention-to-treat analysis. This finding underscored a limitation common to all tocolytic drugs: they delay delivery effectively in the short term but do not fundamentally alter the trajectory of preterm labour.

Atosiban vs. Beta-Agonists

The TREASURE trial (Worldwide Atosiban versus Beta-agonists Study Group, 2001) – a large, multicentre, randomised controlled trial – compared atosiban with the beta-agonist ritodrine in 742 women with preterm labour. Both agents were similarly effective at delaying delivery for 48 hours and 7 days. However, atosiban was associated with significantly fewer maternal cardiovascular side effects: fewer episodes of tachycardia (6% vs. 74%), chest pain (0% vs. 5%), and dyspnoea (0.3% vs. 6.8%).

This dramatically superior tolerability profile has been one of the primary drivers of atosiban’s adoption in Europe, where beta-agonists were previously the standard of care. The TREASURE trial established atosiban as a tocolytic with comparable efficacy but substantially better safety.

Atosiban vs. Nifedipine

A key question in contemporary obstetric practice is whether atosiban or the calcium channel blocker nifedipine should be the first-line tocolytic. The APOSTEL III trial (Van Vliet et al., 2016) – a randomised controlled trial of 510 women – compared nifedipine with atosiban and found no significant difference in the composite neonatal outcome. Both agents were similarly effective at delaying delivery.

Nifedipine had a higher incidence of maternal side effects including hypotension and flushing, while atosiban had a more favourable maternal side-effect profile. However, nifedipine is administered orally and is substantially less expensive, which has led to its preference in resource-limited settings. The NICE guidelines for preterm labour treatment recommend nifedipine as first-line in the UK, while the European Association of Perinatal Medicine supports atosiban as an acceptable alternative (NICE, 2015).

Meta-Analyses and Systematic Reviews

Flenady et al. (2014) conducted a Cochrane systematic review of tocolytic drugs for preterm labour and concluded that atosiban did not reduce the risk of preterm birth compared with placebo when assessed at clinically meaningful endpoints (delivery before 37 weeks). However, the review acknowledged atosiban’s superior safety profile compared with beta-agonists and noted the limited quality of available evidence.

Papatsonis et al. (2005) performed a meta-analysis specifically comparing atosiban with beta-agonists and confirmed equivalent tocolytic efficacy with significantly fewer maternal side effects in the atosiban group. The number needed to treat (NNT) for one additional adverse event with beta-agonists versus atosiban was approximately 6, highlighting the practical clinical advantage.

Side Effects and Safety

Maternal Side Effects

Atosiban is one of the best-tolerated tocolytic drugs available. Common atosiban side effects include:

• Nausea: Reported in approximately 12% of patients, typically mild and self-limiting
• Headache: Occurring in about 10% of patients
• Dizziness: Reported in 4–6% of patients
• Injection site reactions: Local erythema or pain at the infusion site
• Hot flushes: Occasional, mild

Importantly, atosiban does not produce the cardiovascular effects (tachycardia, hypotension, pulmonary oedema) associated with beta-agonists, nor the hepatotoxicity risk of nifedipine, nor the respiratory depression risk of magnesium sulphate. This favourable safety profile makes it particularly suitable for women with cardiovascular comorbidities or multiple pregnancies (de Heus et al., 2009).

Foetal and Neonatal Safety

Atosiban’s foetal safety profile has been extensively evaluated. The drug crosses the placenta, with foetal concentrations reaching approximately 12% of maternal levels (Valenzuela et al., 1995). Long-term follow-up data from the European Atosiban Study Group showed no adverse effects on child development at 2 years of age (Romero et al., 2000).

However, the US Food and Drug Administration declined to approve atosiban in 1998, citing a non-significant numerical excess of foetal deaths in the atosiban group in one early trial, as well as concerns about neonatal outcomes at very early gestational ages (before 26 weeks). These concerns have been addressed in subsequent analyses and meta-analyses, which have not confirmed an increased risk, but the FDA’s position has remained unchanged.

Regulatory Status

Atosiban’s regulatory approval varies by region:

• European Union: Approved (EMA, 2000) for tocolysis between 24 and 33+6 weeks of gestation
• United Kingdom: Available, recommended as a tocolytic option by NICE (2015) alongside nifedipine
• United States: Not approved by the FDA
• Asia: Approved in several countries including South Korea, India, and China
• Latin America: Approved in Brazil and other countries

The disparity between European approval and US non-approval reflects differences in regulatory standards and the specific trial data available at the time of submission, rather than fundamental disagreements about the drug’s pharmacology.

Atosiban in Special Populations

Multiple Pregnancies

Twin and higher-order pregnancies carry a disproportionately high risk of preterm labour. Atosiban’s favourable cardiovascular profile makes it an attractive option in these patients, who are already at increased risk of cardiovascular complications. Al-Omari et al. (2006) reported effective tocolysis with atosiban in twin pregnancies, though controlled trial data specific to multiples remain limited.

Gestational Diabetes

Unlike beta-agonists, which can cause hyperglycaemia through β2-adrenoceptor-mediated glycogenolysis, atosiban has no effect on maternal glucose metabolism. This makes it the preferred tocolytic in women with gestational diabetes or pre-existing diabetes mellitus, eliminating the need for insulin dose adjustments during tocolytic therapy.

Cardiac Disease

The absence of cardiovascular side effects makes atosiban the tocolytic of choice in women with pre-existing cardiac conditions, where beta-agonist-induced tachycardia could be dangerous and calcium channel blockers could cause problematic hypotension.

Emerging Applications

Assisted Reproduction

An intriguing recent application involves the use of atosiban to improve outcomes in in vitro fertilisation (IVF). Moraloglu et al. (2010) conducted a randomised controlled trial demonstrating that atosiban administered during embryo transfer increased implantation and clinical pregnancy rates compared with standard care. The proposed mechanism is that atosiban reduces uterine contractility during the implantation window, creating a more receptive endometrial environment. While these findings require further confirmation, they represent a potential expansion of atosiban’s clinical utility beyond preterm labour.

Dysmenorrhoea

Primary dysmenorrhoea involves excessive myometrial contractions driven in part by oxytocin signalling. While atosiban itself is not practical for this indication due to its intravenous route, the principle of oxytocin receptor blockade for dysmenorrhoea has stimulated the development of oral alternatives that build on atosiban’s proven mechanism. Understanding the role of oxytocin in uterine function and how oxytocin receptor antagonists modulate it is critical for these next-generation therapies.

Comparison with Other Tocolytic Drugs

The following comparison summarises the key characteristics of atosiban relative to other tocolytic drugs:

Atosiban – Route: intravenous; Mechanism: oxytocin receptor antagonist; Key advantage: excellent tolerability, minimal cardiovascular effects; Key limitation: requires IV access, cost.

Nifedipine – Route: oral; Mechanism: calcium channel blockade; Key advantage: oral dosing, low cost; Key limitation: maternal hypotension, headache.

Ritodrine/terbutaline – Route: IV/subcutaneous; Mechanism: β2-adrenoceptor agonism; Key advantage: rapid onset; Key limitation: tachycardia, pulmonary oedema, hyperglycaemia.

Magnesium sulphate – Route: intravenous; Mechanism: calcium competition; Key advantage: dual role as neuroprotectant; Key limitation: respiratory depression, limited tocolytic efficacy.

Indomethacin – Route: oral/rectal; Mechanism: COX inhibition; Key advantage: potent short-term tocolysis; Key limitation: premature ductus arteriosus closure, not used beyond 32 weeks.

The choice of tocolytic depends on gestational age, maternal comorbidities, cost considerations, and local guidelines. The social bonding functions of oxytocin – including its roles in social affiliation and trust – are not affected by the peripheral action of atosiban at therapeutic doses, as the drug has minimal blood–brain barrier penetration. For more on oxytocin’s broader role as the cuddle hormone, see our introductory overview.

Frequently Asked Questions